Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 168024

AbstractMaterial and MethodsResultsDiscussionConclusionAcknowledgementReferencesDOI and Others
Article in PDF How to Cite Citation Manager Readers' Comments (0) Audio Visual Article Statistics Link to PUBMED Print this Article Send to a Friend
Advertisers Access Statistics Resources

Dr Mohan Z Mani

"Thank you very much for having published my article in record time.I would like to compliment you and your entire staff for your promptness, courtesy, and willingness to be customer friendly, which is quite unusual.I was given your reference by a colleague in pathology,and was able to directly phone your editorial office for clarifications.I would particularly like to thank the publication managers and the Assistant Editor who were following up my article. I would also like to thank you for adjusting the money I paid initially into payment for my modified article,and refunding the balance.
I wish all success to your journal and look forward to sending you any suitable similar article in future"



Dr Mohan Z Mani,
Professor & Head,
Department of Dermatolgy,
Believers Church Medical College,
Thiruvalla, Kerala
On Sep 2018




Prof. Somashekhar Nimbalkar

"Over the last few years, we have published our research regularly in Journal of Clinical and Diagnostic Research. Having published in more than 20 high impact journals over the last five years including several high impact ones and reviewing articles for even more journals across my fields of interest, we value our published work in JCDR for their high standards in publishing scientific articles. The ease of submission, the rapid reviews in under a month, the high quality of their reviewers and keen attention to the final process of proofs and publication, ensure that there are no mistakes in the final article. We have been asked clarifications on several occasions and have been happy to provide them and it exemplifies the commitment to quality of the team at JCDR."



Prof. Somashekhar Nimbalkar
Head, Department of Pediatrics, Pramukhswami Medical College, Karamsad
Chairman, Research Group, Charutar Arogya Mandal, Karamsad
National Joint Coordinator - Advanced IAP NNF NRP Program
Ex-Member, Governing Body, National Neonatology Forum, New Delhi
Ex-President - National Neonatology Forum Gujarat State Chapter
Department of Pediatrics, Pramukhswami Medical College, Karamsad, Anand, Gujarat.
On Sep 2018




Dr. Kalyani R

"Journal of Clinical and Diagnostic Research is at present a well-known Indian originated scientific journal which started with a humble beginning. I have been associated with this journal since many years. I appreciate the Editor, Dr. Hemant Jain, for his constant effort in bringing up this journal to the present status right from the scratch. The journal is multidisciplinary. It encourages in publishing the scientific articles from postgraduates and also the beginners who start their career. At the same time the journal also caters for the high quality articles from specialty and super-specialty researchers. Hence it provides a platform for the scientist and researchers to publish. The other aspect of it is, the readers get the information regarding the most recent developments in science which can be used for teaching, research, treating patients and to some extent take preventive measures against certain diseases. The journal is contributing immensely to the society at national and international level."



Dr Kalyani R
Professor and Head
Department of Pathology
Sri Devaraj Urs Medical College
Sri Devaraj Urs Academy of Higher Education and Research , Kolar, Karnataka
On Sep 2018




Dr. Saumya Navit

"As a peer-reviewed journal, the Journal of Clinical and Diagnostic Research provides an opportunity to researchers, scientists and budding professionals to explore the developments in the field of medicine and dentistry and their varied specialities, thus extending our view on biological diversities of living species in relation to medicine.
‘Knowledge is treasure of a wise man.’ The free access of this journal provides an immense scope of learning for the both the old and the young in field of medicine and dentistry as well. The multidisciplinary nature of the journal makes it a better platform to absorb all that is being researched and developed. The publication process is systematic and professional. Online submission, publication and peer reviewing makes it a user-friendly journal.
As an experienced dentist and an academician, I proudly recommend this journal to the dental fraternity as a good quality open access platform for rapid communication of their cutting-edge research progress and discovery.
I wish JCDR a great success and I hope that journal will soar higher with the passing time."



Dr Saumya Navit
Professor and Head
Department of Pediatric Dentistry
Saraswati Dental College
Lucknow
On Sep 2018




Dr. Arunava Biswas

"My sincere attachment with JCDR as an author as well as reviewer is a learning experience . Their systematic approach in publication of article in various categories is really praiseworthy.
Their prompt and timely response to review's query and the manner in which they have set the reviewing process helps in extracting the best possible scientific writings for publication.
It's a honour and pride to be a part of the JCDR team. My very best wishes to JCDR and hope it will sparkle up above the sky as a high indexed journal in near future."



Dr. Arunava Biswas
MD, DM (Clinical Pharmacology)
Assistant Professor
Department of Pharmacology
Calcutta National Medical College & Hospital , Kolkata




Dr. C.S. Ramesh Babu
" Journal of Clinical and Diagnostic Research (JCDR) is a multi-specialty medical and dental journal publishing high quality research articles in almost all branches of medicine. The quality of printing of figures and tables is excellent and comparable to any International journal. An added advantage is nominal publication charges and monthly issue of the journal and more chances of an article being accepted for publication. Moreover being a multi-specialty journal an article concerning a particular specialty has a wider reach of readers of other related specialties also. As an author and reviewer for several years I find this Journal most suitable and highly recommend this Journal."
Best regards,
C.S. Ramesh Babu,
Associate Professor of Anatomy,
Muzaffarnagar Medical College,
Muzaffarnagar.
On Aug 2018




Dr. Arundhathi. S
"Journal of Clinical and Diagnostic Research (JCDR) is a reputed peer reviewed journal and is constantly involved in publishing high quality research articles related to medicine. Its been a great pleasure to be associated with this esteemed journal as a reviewer and as an author for a couple of years. The editorial board consists of many dedicated and reputed experts as its members and they are doing an appreciable work in guiding budding researchers. JCDR is doing a commendable job in scientific research by promoting excellent quality research & review articles and case reports & series. The reviewers provide appropriate suggestions that improve the quality of articles. I strongly recommend my fraternity to encourage JCDR by contributing their valuable research work in this widely accepted, user friendly journal. I hope my collaboration with JCDR will continue for a long time".



Dr. Arundhathi. S
MBBS, MD (Pathology),
Sanjay Gandhi institute of trauma and orthopedics,
Bengaluru.
On Aug 2018




Dr. Mamta Gupta,
"It gives me great pleasure to be associated with JCDR, since last 2-3 years. Since then I have authored, co-authored and reviewed about 25 articles in JCDR. I thank JCDR for giving me an opportunity to improve my own skills as an author and a reviewer.
It 's a multispecialty journal, publishing high quality articles. It gives a platform to the authors to publish their research work which can be available for everyone across the globe to read. The best thing about JCDR is that the full articles of all medical specialties are available as pdf/html for reading free of cost or without institutional subscription, which is not there for other journals. For those who have problem in writing manuscript or do statistical work, JCDR comes for their rescue.
The journal has a monthly publication and the articles are published quite fast. In time compared to other journals. The on-line first publication is also a great advantage and facility to review one's own articles before going to print. The response to any query and permission if required, is quite fast; this is quite commendable. I have a very good experience about seeking quick permission for quoting a photograph (Fig.) from a JCDR article for my chapter authored in an E book. I never thought it would be so easy. No hassles.
Reviewing articles is no less a pain staking process and requires in depth perception, knowledge about the topic for review. It requires time and concentration, yet I enjoy doing it. The JCDR website especially for the reviewers is quite user friendly. My suggestions for improving the journal is, more strict review process, so that only high quality articles are published. I find a a good number of articles in Obst. Gynae, hence, a new journal for this specialty titled JCDR-OG can be started. May be a bimonthly or quarterly publication to begin with. Only selected articles should find a place in it.
An yearly reward for the best article authored can also incentivize the authors. Though the process of finding the best article will be not be very easy. I do not know how reviewing process can be improved. If an article is being reviewed by two reviewers, then opinion of one can be communicated to the other or the final opinion of the editor can be communicated to the reviewer if requested for. This will help one’s reviewing skills.
My best wishes to Dr. Hemant Jain and all the editorial staff of JCDR for their untiring efforts to bring out this journal. I strongly recommend medical fraternity to publish their valuable research work in this esteemed journal, JCDR".



Dr. Mamta Gupta
Consultant
(Ex HOD Obs &Gynae, Hindu Rao Hospital and associated NDMC Medical College, Delhi)
Aug 2018




Dr. Rajendra Kumar Ghritlaharey

"I wish to thank Dr. Hemant Jain, Editor-in-Chief Journal of Clinical and Diagnostic Research (JCDR), for asking me to write up few words.
Writing is the representation of language in a textual medium i e; into the words and sentences on paper. Quality medical manuscript writing in particular, demands not only a high-quality research, but also requires accurate and concise communication of findings and conclusions, with adherence to particular journal guidelines. In medical field whether working in teaching, private, or in corporate institution, everyone wants to excel in his / her own field and get recognised by making manuscripts publication.


Authors are the souls of any journal, and deserve much respect. To publish a journal manuscripts are needed from authors. Authors have a great responsibility for producing facts of their work in terms of number and results truthfully and an individual honesty is expected from authors in this regards. Both ways its true "No authors-No manuscripts-No journals" and "No journals–No manuscripts–No authors". Reviewing a manuscript is also a very responsible and important task of any peer-reviewed journal and to be taken seriously. It needs knowledge on the subject, sincerity, honesty and determination. Although the process of reviewing a manuscript is a time consuming task butit is expected to give one's best remarks within the time frame of the journal.
Salient features of the JCDR: It is a biomedical, multidisciplinary (including all medical and dental specialities), e-journal, with wide scope and extensive author support. At the same time, a free text of manuscript is available in HTML and PDF format. There is fast growing authorship and readership with JCDR as this can be judged by the number of articles published in it i e; in Feb 2007 of its first issue, it contained 5 articles only, and now in its recent volume published in April 2011, it contained 67 manuscripts. This e-journal is fulfilling the commitments and objectives sincerely, (as stated by Editor-in-chief in his preface to first edition) i e; to encourage physicians through the internet, especially from the developing countries who witness a spectrum of disease and acquire a wealth of knowledge to publish their experiences to benefit the medical community in patients care. I also feel that many of us have work of substance, newer ideas, adequate clinical materials but poor in medical writing and hesitation to submit the work and need help. JCDR provides authors help in this regards.
Timely publication of journal: Publication of manuscripts and bringing out the issue in time is one of the positive aspects of JCDR and is possible with strong support team in terms of peer reviewers, proof reading, language check, computer operators, etc. This is one of the great reasons for authors to submit their work with JCDR. Another best part of JCDR is "Online first Publications" facilities available for the authors. This facility not only provides the prompt publications of the manuscripts but at the same time also early availability of the manuscripts for the readers.
Indexation and online availability: Indexation transforms the journal in some sense from its local ownership to the worldwide professional community and to the public.JCDR is indexed with Embase & EMbiology, Google Scholar, Index Copernicus, Chemical Abstracts Service, Journal seek Database, Indian Science Abstracts, to name few of them. Manuscriptspublished in JCDR are available on major search engines ie; google, yahoo, msn.
In the era of fast growing newer technologies, and in computer and internet friendly environment the manuscripts preparation, submission, review, revision, etc and all can be done and checked with a click from all corer of the world, at any time. Of course there is always a scope for improvement in every field and none is perfect. To progress, one needs to identify the areas of one's weakness and to strengthen them.
It is well said that "happy beginning is half done" and it fits perfectly with JCDR. It has grown considerably and I feel it has already grown up from its infancy to adolescence, achieving the status of standard online e-journal form Indian continent since its inception in Feb 2007. This had been made possible due to the efforts and the hard work put in it. The way the JCDR is improving with every new volume, with good quality original manuscripts, makes it a quality journal for readers. I must thank and congratulate Dr Hemant Jain, Editor-in-Chief JCDR and his team for their sincere efforts, dedication, and determination for making JCDR a fast growing journal.
Every one of us: authors, reviewers, editors, and publisher are responsible for enhancing the stature of the journal. I wish for a great success for JCDR."



Thanking you
With sincere regards
Dr. Rajendra Kumar Ghritlaharey, M.S., M. Ch., FAIS
Associate Professor,
Department of Paediatric Surgery, Gandhi Medical College & Associated
Kamla Nehru & Hamidia Hospitals Bhopal, Madhya Pradesh 462 001 (India)
E-mail: drrajendrak1@rediffmail.com
On May 11,2011




Dr. Shankar P.R.

"On looking back through my Gmail archives after being requested by the journal to write a short editorial about my experiences of publishing with the Journal of Clinical and Diagnostic Research (JCDR), I came across an e-mail from Dr. Hemant Jain, Editor, in March 2007, which introduced the new electronic journal. The main features of the journal which were outlined in the e-mail were extensive author support, cash rewards, the peer review process, and other salient features of the journal.
Over a span of over four years, we (I and my colleagues) have published around 25 articles in the journal. In this editorial, I plan to briefly discuss my experiences of publishing with JCDR and the strengths of the journal and to finally address the areas for improvement.
My experiences of publishing with JCDR: Overall, my experiences of publishing withJCDR have been positive. The best point about the journal is that it responds to queries from the author. This may seem to be simple and not too much to ask for, but unfortunately, many journals in the subcontinent and from many developing countries do not respond or they respond with a long delay to the queries from the authors 1. The reasons could be many, including lack of optimal secretarial and other support. Another problem with many journals is the slowness of the review process. Editorial processing and peer review can take anywhere between a year to two years with some journals. Also, some journals do not keep the contributors informed about the progress of the review process. Due to the long review process, the articles can lose their relevance and topicality. A major benefit with JCDR is the timeliness and promptness of its response. In Dr Jain's e-mail which was sent to me in 2007, before the introduction of the Pre-publishing system, he had stated that he had received my submission and that he would get back to me within seven days and he did!
Most of the manuscripts are published within 3 to 4 months of their submission if they are found to be suitable after the review process. JCDR is published bimonthly and the accepted articles were usually published in the next issue. Recently, due to the increased volume of the submissions, the review process has become slower and it ?? Section can take from 4 to 6 months for the articles to be reviewed. The journal has an extensive author support system and it has recently introduced a paid expedited review process. The journal also mentions the average time for processing the manuscript under different submission systems - regular submission and expedited review.
Strengths of the journal: The journal has an online first facility in which the accepted manuscripts may be published on the website before being included in a regular issue of the journal. This cuts down the time between their acceptance and the publication. The journal is indexed in many databases, though not in PubMed. The editorial board should now take steps to index the journal in PubMed. The journal has a system of notifying readers through e-mail when a new issue is released. Also, the articles are available in both the HTML and the PDF formats. I especially like the new and colorful page format of the journal. Also, the access statistics of the articles are available. The prepublication and the manuscript tracking system are also helpful for the authors.
Areas for improvement: In certain cases, I felt that the peer review process of the manuscripts was not up to international standards and that it should be strengthened. Also, the number of manuscripts in an issue is high and it may be difficult for readers to go through all of them. The journal can consider tightening of the peer review process and increasing the quality standards for the acceptance of the manuscripts. I faced occasional problems with the online manuscript submission (Pre-publishing) system, which have to be addressed.
Overall, the publishing process with JCDR has been smooth, quick and relatively hassle free and I can recommend other authors to consider the journal as an outlet for their work."



Dr. P. Ravi Shankar
KIST Medical College, P.O. Box 14142, Kathmandu, Nepal.
E-mail: ravi.dr.shankar@gmail.com
On April 2011
Anuradha

Dear team JCDR, I would like to thank you for the very professional and polite service provided by everyone at JCDR. While i have been in the field of writing and editing for sometime, this has been my first attempt in publishing a scientific paper.Thank you for hand-holding me through the process.


Dr. Anuradha
E-mail: anuradha2nittur@gmail.com
On Jan 2020

Important Notice

Original article / research
Year : 2026 | Month : December | Volume : 20 | Issue : 12 | Page : DC10 - DC17 Full Version

Bacteriological Profile and Antimicrobial Resistance Patterns of Skin and Soft-tissue Infections: A Five-year Retrospective Study


Published: December 1, 2026 | DOI: https://doi.org/10.7860/JCDR/2026/89158.24694
DV Viswanathan, Prashant Patil, Ashish Sadafale, PL Kashyap, Sunil Bhamare, Chhaya Chande, Rajesh Karyakarte

1. Junior Resident, Department of Microbiology, BJGMC&SGH, Pune, Maharashtra, India. 2. Assistant Professor, Department of Microbiology, BJGMC&SGH, Pune, Maharashtra, India. 3. Assistant Professor, Department of Microbiology, BJGMC&SGH, Pune, Maharashtra, India. 4. Assistant Professor, Department of Microbiology, BJGMC&SGH, Pune, Maharashtra, India. 5. Associate Professor, Department of Microbiology, BJGMC&SGH, Pune, Maharashtra, India. 6. Professor, Department of Microbiology, BJGMC&SGH, Pune, Maharashtra, India. 7. Professor and Head, Department of Microbiology, BJGMC&SGH, Pune, Maharashtra, India.

Correspondence Address :
Dr. Prashant Patil,
Assistant Professor, Department of Microbiology, 1st Floor, College Building, BJGMC&SGH, Railway Station Road, Agarkar Nagar, Pune-411001, Maharashtra, India.
E-mail: dr.prpatil@gmail.com

Abstract

Introduction: Skin and Soft-Tissue Infections (SSTIs) constitute a major burden of infectious diseases and are among the most common conditions encountered in clinical practice. The emergence and rapid spread of antimicrobial resistance among pathogens causing SSTIs have significantly limited therapeutic options, increasing morbidity, prolonging hospital stays, and raising healthcare costs. Periodic surveillance of the bacteriological profile and antimicrobial susceptibility patterns of pus isolates is essential to guide empirical therapy and strengthen antimicrobial stewardship in tertiary care settings.

Aim: To determine the bacteriological profile and antimicrobial resistance patterns of pathogens isolated from SSTI.

Materials and Methods: This retrospective observational study was conducted in the Department of Microbiology, BJ Government Medical College and Sassoon General Hospital, Pune, Maharashtra, India, from January 2020 to December 2024. Laboratory records of pus samples received were reviewed. Data extraction, compilation and analysis were performed between October 2025 and January 2026. Bacterial isolates were identified using standard microbiological techniques, and antimicrobial susceptibility was assessed by standardised antimicrobial susceptibility testing methods. The bacteriological profile, antimicrobial resistance patterns, and prevalence of Multidrug-Resistant (MDR), Extensively Drug-Resistant (XDR), Carbapenem-Resistant Enterobacterales (CRE), Methicillin-Resistant Staphylococcus aureus (MRSA), and Extended-Spectrum b-Lactamase (ESBL)-producing isolates were assessed. Data were analysed using descriptive statistics and the Chi-square test for trend where applicable. A p-value<0.05 was considered statistically significant.

Results: A total of 18,391 pus samples were received and wound swabs processed; 10,264 (55.8%) showed significant bacterial growth. Gram Negative Bacilli (GNB) predominated, accounting for 8,039 (78.3%) isolates, while Gram positive Cocci (GPC) constituted 2,225 (21.7%). Escherichia coli 2638 (25.7%) was the most common Gram negative isolate, followed by Klebsiella pneumoniae 2361 (23.0%) and Pseudomonas aeruginosa 1540 (15%). Among GPC, Staphylococcus aureus was predominant 1755 (17.1%). A high burden of antimicrobial resistance was observed, with 7,027 (68.4%) isolates classified as MDR and 5,071 (49.4%) as XDR. Extended-spectrum beta-lactamase production was noted in 4,697 (58.4%) of Gram negative isolates, and carbapenem resistance was observed in 3,085 (38.4%). Among S. aureus isolates, 1,038 (59.1%) were MRSA.

Conclusion: The study demonstrated a predominance of gram negative pathogens and a high prevalence of MDR among bacteria causing SSTI. High burdens of MDR, XDR, ESBL-producing, and carbapenem-resistant organisms were observed, with statistically significant increasing trends identified for selected organisms and resistance phenotypes.

Keywords

Carbapenem resistance, Drug resistance, Extended-spectrum beta-lactamases, Methicillin-resistant Staphylococcus aureus

The SSTIs encompass a wide range of infections affecting the epidermis, dermis, subcutaneous tissue, fascia, or muscle. Disruption of the skin barrier due to trauma, surgery, burns, or systemic illness facilitates microbial invasion and infection. Pyogenic infections, characterised by suppurative inflammation and pus formation composed of necrotic debris, leukocytes, and microorganisms, are an important cause of sepsis (1).

The bacterial aetiology of SSTIs is diverse and may be monomicrobial or polymicrobial, involving both GPC and GNB. Although Staphylococcus aureus has traditionally been regarded as the predominant pathogen, recent studies from tertiary care centres indicate an increasing predominance of GNB -such as Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter species- particularly in complicated and hospital-acquired wound infections (2). The emergence and spread of antibiotic-resistant strains pose a major challenge in management, significantly limiting therapeutic options and contributing to increased morbidity, mortality, and healthcare costs worldwide (3).
According to the Global Burden of Disease Study, 4.71 million deaths were associated with bacterial AMR in 2021, including 1.14 million directly attributable deaths. By 2050, AMR deaths are projected to reach 1.91 million attributable and 8.22 million associated globally. Overall deaths are expected to increase by 69.6% (2022-2050), while Disability-Adjusted Life Years (DALYs) will rise modestly by 9.4% to 46.5 million (4). India accounts for a significant share of the global AMR burden due to widespread antibiotic misuse and overuse. AMR in India is escalating, particularly resistance to extended-spectrum cephalosporins and carbapenems. Emerging colistin resistance, NDM prevalence, and novel resistance mechanisms are further limiting therapeutic options. Additionally, rates of MRSA and Vancomycin-Resistant Enterococcus (VRE), especially E. faecium, continue to rise (5).

In 2015, the World Health Organisation (WHO) endorsed the Global Action Plan on AMR (GAP-AMR) to preserve antimicrobial effectiveness through rational use, surveillance, and research across human, animal, and agricultural sectors (6). WHO further recommends that ≥70% of human antibiotic consumption come from the Access, Watch and Reserve (AWaRe) Access group and urges countries to strengthen Antimicrobial Use (AMU) reporting to the Global Antimicrobial Resistance and Use Surveillance System (GLASS) by 2030 (7).

In India, the Indian Council of Medical Research (ICMR) released Antimicrobial Stewardship Program guidelines in 2018 to support hospital Antimicrobial Stewardship (AMS) implementation. Earlier, in 2017, the Ministry of Health and Family Welfare launched the National Action Plan (NAP) on AMR (2017-2021) using a One Health approach, followed by NAP-AMR (2025-2029) to address implementation gaps (8).

The bacteriological profile and antimicrobial susceptibility patterns of SSTI pathogens vary considerably across geographical regions and healthcare settings. Therefore, periodic local surveillance is essential to monitor changing epidemiological trends, detect emerging resistance phenotypes, and formulate evidence-based empirical treatment guidelines. However, long-term Institution-specific data on SSTI pathogens and their resistance patterns remain limited in many tertiary care hospitals (9). The present study aimed to evaluate the bacteriological profile of SSTI and determine the antimicrobial susceptibility patterns of bacterial isolates recovered from pus samples over five years in a tertiary care hospital.

Material and Methods

This retrospective observational study was conducted in the Department of Microbiology, BJ Government Medical College and Sassoon General Hospital, Pune, Maharashtra, India, from January 2020 to December 2024. Laboratory records of pus samples received were retrospectively reviewed. Data extraction, compilation and analysis were performed between October 2025 and January 2026 following approval from the Institutional Ethics Committee (BJGMC/IEC/Pharmac/ND-0925310-310, September 2025). Since the study involved retrospective analysis of anonymised laboratory records generated as part of routine patient care, the requirement for individual informed consent was waived by the Ethics Committee.

Sample size: This was a time-bound retrospective study. All eligible pus specimens received during the study period were included. A total of 18,391 pus samples were received from patients with clinically suspected SSTI attending Outpatient Departments (OPD), inpatient wards and Intensive Care Units (ICU).

Inclusion criteria: All pus aspirates and wound swabs received in the Department of Microbiology from patients with clinically suspected SSTI during the study period were included, and samples were processed according to standard microbiological laboratory protocols. Only aerobic bacterial isolates were included in the analysis.

Exclusion criteria: Specimens that were improperly collected, leaked, or inadequately labelled were excluded from the analysis. Duplicate isolates were also excluded, with only the first isolate of the same organism per patient per calendar year included, in accordance with Clinical and Laboratory Standards Institute (CLSI) M39 guidelines (10).

Specimens yielding mixed growth of more than two bacterial species were considered likely to represent colonisation or contamination and were excluded from susceptibility trend analysis. Additionally, anaerobic and fungal isolates were excluded.

Study Procedure

Sample collection and transport: Pus aspirates were routinely collected in sterile leak-proof containers, while wound swabs were 11collected using two sterile cotton swabs, one for gram staining and the other for culture and antimicrobial susceptibility testing. Specimens were transported immediately to the Microbiology laboratory at ambient temperature without transport medium and processed within two hours of receipt whenever possible as part of routine laboratory practice.

Microbiological processing and identification: As part of routine diagnostic laboratory procedures, all specimens were inoculated onto Nutrient Agar, 5% Sheep Blood Agar and MacConkey Agar and incubated aerobically at 37°C. Plates showing no growth after 24 hours were reincubated for an additional 24 hours before being reported as culture-negative.

Direct gram-stained smears were examined for pus cells and microorganisms. Bacterial identification was performed manually using standard microbiological methods based on colony morphology, gram staining characteristics, motility testing and conventional biochemical reactions.

For GNB, identification included combinations of indole, citrate utilisation, urease, triple sugar iron agar reaction, oxidase test, motility and lysine decarboxylase tests. For GPC, catalase, coagulase, bile esculin hydrolysis and Pyrrolidonyl Arylamidase (PYR) tests were used as appropriate. Identification procedures followed standard microbiological protocols and CLSI (2022) recommendations applicable during the study period (10).

Antimicrobial susceptibility testing: Antimicrobial susceptibility testing was routinely performed using the Kirby-Bauer disc diffusion method on Mueller-Hinton agar according to CLSI M100 guidelines (2026) (11). Inoculum density was standardised to 0.5 McFarland turbidity, and plates were incubated aerobically at 35±2°C for 16-18 hours before interpretation.

The antibiotic panel tested for gram negative isolates included ampicillin, amoxicillin-clavulanate, piperacillin-tazobactam, cefuroxime, ceftazidime, ceftriaxone, cefotaxime, cefepime, aztreonam, imipenem, meropenem, amikacin, gentamicin, ciprofloxacin, cotrimoxazole, doxycycline, minocycline, tetracycline and colistin.

The antibiotic panel tested for gram positive isolates included penicillin, cefoxitin, gentamicin, ciprofloxacin, cotrimoxazole, clindamycin, erythromycin, doxycycline, tetracycline, vancomycin, teicoplanin and linezolid.

All antibiotic discs were procured from HiMedia Laboratories, Mumbai, India and used according to the manufacturer’s instructions.

Detection of Methicillin-Resistant Staphylococcus Aureus (MRSA): Methicillin resistance among Staphylococcus aureus isolates was determined using the cefoxitin (30 μg) disc diffusion method on Mueller-Hinton agar according to CLSI M100 guidelines, 36th edition (2026) (11). Staphylococcus aureus ATCC 25923 was used as the quality control strain.

Detection of vancomycin resistance: Vancomycin resistance screening was performed using vancomycin screen agar containing 6 μg/mL vancomycin. Plates were incubated at 35°C for 24 hours and interpreted according to CLSI M100 guidelines, 36th edition (2026) (11). Staphylococcus aureus ATCC 29213 was used for quality control.

Colistin susceptibility testing: Colistin susceptibility among Gram negative isolates was determined using broth microdilution according to CLSI M100 guidelines, 36th edition (2026) (11). An MIC ≥4 μg/mL was considered resistant. Escherichia coli ATCC 25922 was used for quality control.

Detection of Extended-Spectrum b-Lactamase (ESBL): The ESBL production was detected by the combined disc method using ceftazidime (30 μg) and cefotaxime (30 μg) alone and in combination with clavulanic acid (10 μg) on Mueller–Hinton agar.

Plates were incubated at 35±2°C for 16-18 hours. An increase of ≥5 mm in inhibition zone diameter in the presence of clavulanate was interpreted as ESBL production. Klebsiella pneumoniae ATCC 700603 served as the quality control strain.

The CRE were defined according to Centres for Disease Control and Prevention (CDC) criteria (12) as Enterobacterales exhibiting resistance to at least one carbapenem agent, including ertapenem, doripenem, imipenem, or meropenem. MDR and XDR were defined according to the international expert proposal by Magiorakos AP et al., with MDR defined as non susceptibility to at least one agent in three or more antimicrobial categories, and XDR defined as non susceptibility to at least one agent in all but two or fewer antimicrobial categories (13).

STATISTICAL ANALYSIS

Data were compiled using WHO NET version 5.6 and analysed using Microsoft Excel 2021 and IBM Statistical Package for Social Sciences (SPSS) Statistics version 26.0. Categorical variables were expressed as frequencies and percentages. Year-wise trends in antimicrobial resistance were assessed using the Chi-square test for trend (Cochran-Armitage trend test where applicable). A p-value <0.05 was considered statistically significant.


Results

A total of 18,391 pus samples were received in the Department of Microbiology. Of these, 10,264 (55.8%) yielded significant bacterial growth, whereas 8,127 (44.2%) showed no growth. The year-wise distribution of pus samples received and culture positivity rates is presented in (Table/Fig 1).

The annual distribution of GNB and GPC isolated from culture-positive specimens is shown in (Table/Fig 2).

Among the culture-positive cases, male patients predominated, with a male-to-female ratio of 2.1:1. The highest incidence of infections was observed in the 31-45 years age group, 4311 (42%), followed by individuals aged >45 years, 3182 (31%), 15-30 years, 2297 (22%), and 0-14 years, 474 (5%).

Based on the source of sample collection, the majority of specimens were obtained from inpatients 8594 (84%), followed by OPD patients 1193 (11%), and ICU patients 477 (5%). On microbiological analysis, GNB constituted the predominant isolates, accounting for 8,039 (78.3%), while GPC comprised 2,225 (21.7%) of the total isolates.

Among GPC, coagulase-positive Staphylococcus aureus was the most common isolate, accounting for 1,755 isolates (17.1%), followed by Enterococcus spp. (236; 2.3%) and Coagulase-Negative Staphylococci (CoNS) (185; 1.8%). Among GNB, Escherichia coli (2,638; 25.7%) was the predominant organism, followed by Klebsiella pneumoniae (2,361; 23.0%). Among non fermenting GNB, Pseudomonas aeruginosa (1,540; 15%) was the most frequently isolated organism, followed by Acinetobacter baumannii complex (708; 6.9%). Rare pathogens such as Burkholderia pseudomallei (n=1) and Serratia marcescens (n=1) were also isolated (Table/Fig 3).

Out of the total 10,264 bacterial isolates, 7,027 (68.4%) were classified as MDR and 5,071 (49.4%) were categorised as XDR. Among GPC, 1,305 isolates (12.7%) were MDR and 783 (7.6%) were XDR, whereas among GNB, 5,722 isolates (55.7%) were MDR and 4,288 (41.8%) were XDR. ESBL production was identified in 4,697 isolates (58.4%) of GNB, while CRE accounted for 3,085 isolates (38.4%) (Table/Fig 4).

Among E. coli, resistance to ampicillin remained extremely high (91.1-96.9%), with similarly elevated resistance to third-generation cephalosporins such as ceftriaxone (86.7-91.1%) and cefotaxime (74.4-88.2%). Ciprofloxacin resistance persisted at high levels (69.2-80.9%). Notably, carbapenem resistance increased over time, with imipenem rising from 17.0% (2020) to 44.8% (2024) and meropenem reaching 35.9% in 2024 (Table/Fig 5).

In Klebsiella spp., resistance to cephalosporins remained high (≥82%), and ciprofloxacin resistance ranged from 62.5% to 84.7%. Carbapenem resistance was considerable and showed an upward trend, with imipenem and meropenem resistance reaching 65.7% and 60.0%, respectively, in 2024.

For Proteus vulgaris and Proteus mirabilis (2023-2024), high resistance was observed to cephalosporins (up to 80.6%), ciprofloxacin (66.7-77.6%), and cotrimoxazole (60.5-78.3%). Carbapenem resistance was moderate to high, particularly for imipenem (45.5-63.6%). Overall, the findings reflect sustained high ESBL-associated resistance and rising carbapenem resistance, especially among Klebsiella spp.

Among non fermenting GNB, Pseudomonas spp. showed moderate but rising resistance to piperacillin-tazobactam (20.6-37.8%), carbapenems (imipenem 21.9-47.6%; meropenem 19.7-31.1%), and ciprofloxacin (34.3-58.1%), with ceftazidime and cefepime resistance around 40-53%. Acinetobacter spp. exhibited resistance to several antimicrobial classes, including piperacillin-tazobactam (67.7-80.0%), ceftazidime (66.7-87.3%), carbapenems (46.4-76.0%), and ciprofloxacin (60.0-85.6%). Colistin resistance was found to be minimal across all tested organisms, with prevalence rates remaining below 1% (Table/Fig 6).

Out of 1,755 S. aureus isolates, 1,038 (59.1%) were identified as cefoxitin-resistant (MRSA), while the remaining isolates were cefoxitin-susceptible (MSSA). Staphylococcus aureus showed persistently high penicillin resistance (91.3-93.9%). Cefoxitin resistance (MRSA marker) increased from 56.0% in 2020 to 68.0% in 2024, indicating a rising MRSA trend. Ciprofloxacin resistance fluctuated widely (31.4-76.8%), peaking at 76.8% in 2024, while erythromycin remained consistently high (39.4-62.8%). Clindamycin showed moderate resistance (22.5-39.8%). Gentamicin resistance declined overall to 13.5% in 2024.

Cotrimoxazole resistance steadily decreased from 25.7% (2020) to 7.7% (2024). Doxycycline (6.6% in 2024) and tetracycline (8.2% in 2024) maintained low resistance rates. Vancomycin, linezolid, and tigecycline showed 0% resistance throughout the study period (Table/Fig 7).

The CoNS isolates had high resistance to penicillin (94.8%), ciprofloxacin (69.9%), and erythromycin (71.6%), while remaining fully susceptible to vancomycin. Enterococcus spp. demonstrated moderate ampicillin resistance (42.1%) and high erythromycin resistance (65.5%). A progressive increase in the total number of S. aureus isolates was observed over the study period, with MRSA consistently predominating over MSSA in all years. No isolates of Vancomycin-Intermediate S. aureus (VISA), Vancomycin-Resistant S. aureus (VRSA), or VRE were detected during the study period (Table/Fig 8).







Discussion

The SSTIs remain a significant cause of morbidity in both community and hospital settings, particularly in tertiary care centres catering to referral patients. The present five-year retrospective study provides a comprehensive overview of the bacteriological profile and antimicrobial resistance patterns among pus isolates and highlights a sustained and increasing burden of MDR organisms.

In the present study, culture positivity was observed in 56% of pus samples, which is comparable to reports from similar tertiary care settings in India. Studies by Trojan R et al., have documented culture positivity rates of 60.1% and 60.5% Manoj K et al., in pus samples, reflecting a similar burden of pyogenic infections in tertiary healthcare facilities (9),(14). In the present study, males had a wound infection rate 2.1 times higher than females. This may be attributed to men’s greater likelihood of working outdoors, which increases their risk of injury and exposure to contaminated environments. Sudhaharan S et al., also noted a similar trend, reporting a male-to-female ratio of 2.5:1 for wound infections (15).

The predominance of GNB (78.3%) over GPC in the present study aligns with recent Indian reports, reflecting a shift from the traditionally described Gram-positive dominance in SSTIs toward Gram negative pathogens, particularly in hospital-acquired and complicated wound infections (14). Among the gram negative isolates, Escherichia coli and Klebsiella pneumoniae were the most common, followed by Pseudomonas aeruginosa and the Acinetobacter baumannii complex. Similar distribution patterns have been documented in multicentric Indian studies and national surveillance data, indicating widespread dissemination of these organisms across healthcare settings [9,15,16]. Over the five years (2020-2024), although the spectrum of pathogens remained largely unchanged, a progressive increase in antimicrobial resistance was observed. The notable presence of non fermenting GNB, particularly Pseudomonas aeruginosa and Acinetobacter baumannii complex, is clinically significant, as these organisms are associated with biofilm formation, prolonged hospitalisation, and limited therapeutic options, as highlighted by Peleg AY et al., (17).

A high prevalence of MDR was observed in the present study, with 68.4% of isolates classified as MDR and nearly half as XDR. Comparable findings have been reported by Ingale HD, who documented MDR rates exceeding 60% among pus isolates from tertiary care hospitals (16). The higher proportion of MDR and XDR among GNB compared to GPC further underscores the therapeutic challenges posed by these organisms and reflects increasing antimicrobial pressure in hospital settings.

The ESBL production was detected in 58.4% of gram negative isolates in the present study. A comparable study by Sharma S et al., from a tertiary care centre in Western Maharashtra, reported a slightly higher prevalence (67.8%), while Umadevi S et al., documented an ESBL rate of 69%, indicating consistently high ESBL burden across tertiary care settings (18),(19). The high ESBL burden significantly limits the utility of third-generation cephalosporins for empirical therapy and contributes to increased carbapenem use, thereby accelerating the emergence of carbapenem resistance. In the present study, CRE accounted for 38.4% of gram negative isolates, reflecting an alarming rise consistent with trends reported by National Surveillance Data (2022) (20),(21).

Among non fermenters, Acinetobacter baumannii demonstrated high levels of resistance across multiple antimicrobial classes, corroborating findings reported by National surveillance data, where carbapenem resistance rates exceeding 80% have been observed, particularly in intensive care settings [20,21]. Although comprehensive national data on colistin resistance among nosocomial pathogens in India remain limited, some studies have reported resistance rates as high as 9.98% (22). However, surveillance data from the Indian Council of Medical Research indicate lower rates (3-6%), while the National Antimicrobial Resistance Surveillance Network reports resistance of <1% in most organisms (20),(21). In the present study, colistin resistance was minimal, with rates below 1%, suggesting preserved susceptibility in this setting.

Among GPC, Staphylococcus aureus remained the predominant isolate, with methicillin resistance detected in 59.1% of isolates. Similar results were observed in the study by Singh A et al., (23); MRSA was 52.2%, and MSSA was 41.2%, and another study reported by Patil P et al., (24) the MRSA was 56.1% and MSSA was 43.9%. The absence of VISA or VRSA and VRE in the present study is encouraging. National surveillance data ICMR reports an MRSA prevalence of 44.5%, while the National Antimicrobial Resistance Surveillance Network (NARS-Net) documents a higher rate of 59%. Vancomycin resistance in Enterococcus faecium (27%) and Enterococcus faecalis (5%) has been reported by ICMR, whereas NARS-Net reports an overall VRE prevalence of 13% (20),(21). These data highlight a sustained MRSA burden and the growing concern of vancomycin resistance among Enterococci in Indian healthcare settings. These findings underscore the importance of continuous local surveillance, regular antibiogram generation, and strict implementation of antimicrobial stewardship and infection prevention strategies, as advocated by WHO and national expert groups (21).

Limitation(s)

The present study has certain limitations. As a retrospective, single-centre, laboratory-based study, important clinical details such as infection severity, prior antibiotic use, treatment outcomes, and patient comorbidities could not be reliably assessed. Detailed clinical information regarding the specific type of SSTI was not uniformly available; therefore, infection-specific subgroup analysis could not be performed. Being conducted at a tertiary care referral hospital, the study may be subject to referral bias, and the findings may not be directly generalizable to other healthcare settings. The study was limited to aerobic bacterial isolates recovered from pus samples; anaerobic bacteria and fungal pathogens were not evaluated, which may have led to underestimation of the complete microbiological spectrum of SSTIs. Molecular confirmation of resistance mechanisms, including ESBL, carbapenemase, and methicillin resistance, was not performed due to resource constraints.




Conclusion

The present five-year retrospective study demonstrates a predominance of GNB and a high burden of antimicrobial resistance in SSTI, likely driven by the ongoing spread of resistance genes. As a tertiary referral centre, prior treatment and exposure to broad-spectrum antibiotics among patients may have contributed to the selection of MDR strains. The year-wise increase in MDR, XDR, ESBL-producing, and CRE isolates reflects the combined impact of antibiotic pressure, prolonged hospitalisation, and referral patterns typical of such settings. The considerable proportion of MRSA further highlights the need for vigilant surveillance. Institution-specific antimicrobial susceptibility data can guide appropriate empirical therapy and strengthen antimicrobial stewardship efforts. Enhanced infection control measures and judicious antibiotic use are essential to curb the emergence and spread of antimicrobial resistance.

Acknowledgement

The authors would like to acknowledge the support and assistance of the laboratory staff for their technical help and cooperation during the conduct of the present study. No financial or material support was received, and the research was carried out without any external funding.

References

1.
Koneman EW, Allen SD, Janda WM, Schreckenberger PC, Procop GW, Woods GL. Color Atlas and Textbook of Diagnostic Microbiology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 624-62.
2.
Basak S, Singh P, Rajurkar M. Multidrug-resistant and extensively drug-resistant bacteria: A study. J Pathog. 2016;2016:4065603. [crossref] [PubMed]
3.
Morales E, Cots F, Sala M, Comas M, Belvis F, Riu M, et al. Hospital costs of nosocomial multidrug-resistant Pseudomonas aeruginosa acquisition. BMC Health Serv Res. 2012;12:122. [crossref] [PubMed]
4.
Naghavi M, Vollset SE, Ikuta KS, Swetschinski LR, Gray AP, Wool EE, et al. Global burden of bacterial antimicrobial resistance 1990-2021: A systematic analysis with forecasts to 2050. Lancet. 2024;404(10459):1199-226. [crossref] [PubMed]
5.
Chakrabarti A, Balaji V, Bansal N, Gopalakrishnan R, Gupta P, Jain A, et al. NAMS task force report on antimicrobial resistance. Ann Natl Acad Med Sci (India). 2025;61:171-209. [crossref]
6.
World Health Organization. Global action plan on antimicrobial resistance [Internet]. Geneva: World Health Organization; 2015 [cited 2026 Jun 26]. Available from: https://iris.who.int/handle/10665/193736.
7.
World Health Organization. Global antimicrobial resistance and use surveillance system (GLASS) report 2022 [Internet]. Geneva: World Health Organization; 2022 [cited 2026 Jun 26]. Available from: https://www.who.int/initiatives/glass.
8.
Ministry of Health and Family Welfare. National action plan on antimicrobial resistance (NAP-AMR) 2025-2029 [Internet]. New Delhi: Government of India; 2025 [cited 2026 Jun 26]. Available from: https://ncdc.mohfw.gov.in.
9.
Trojan R, Razdan L, Singh N. Antibiotic susceptibility patterns of bacterial isolates from pus samples in a tertiary care hospital of Punjab, India. Int J Microbiol. 2016;2016:9302692. [crossref] [PubMed]
10.
Clinical and Laboratory Standards Institute. M39: Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data. 5th ed. Wayne (PA): Clinical and Laboratory Standards Institute; 2022.
11.
Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 36th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2026.
12.
Centers for Disease Control and Prevention. About carbapenem-resistant Enterobacterales (CRE). Atlanta (GA): CDC; 2025 [cited 2026 Jun 26]. Available from: https://www.cdc.gov/cre/about.
13.
Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268-81. [crossref] [PubMed]
14.
Kumar M, Lakra N, Sharma AK, Prasad A, Seema K. Bacterial profile and antibiogram of pus isolates in a tertiary care hospital. IOSR J Dent Med Sci. 2020;19(5):09-14.
15.
Sudhaharan S, Kanne P, Chavali P, Vemu L. Aerobic bacteriological profile and antimicrobial susceptibility pattern of pus isolates from a tertiary care hospital in India. J Infect Dev Ctries. 2018;12(10):842-48. [crossref] [PubMed]
16.
Ingale HD. Multidrug resistance in bacterial isolates from pus samples: A hospital-based descriptive cross-sectional study. Natl J Lab Med. 2024;13(3):MO20-MO24. [crossref]
17.
Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: Emergence of a successful pathogen. Clin Microbiol Rev. 2008;21(3):538-82. [crossref] [PubMed]
18.
Sharma S, Karande G, Patil S. An insight into the bacteriological profile: Escalating antimicrobial resistance patterns and the spectrum of multidrug-resistant Enterobacteriaceae at a tertiary care center in Western Maharashtra. Cureus. 2024;16(9):e69538. [crossref]
19.
Umadevi S, Kandhakumari G, Joseph NM, Kumar S, Easow JM, Stephen S, et al. Prevalence and antimicrobial susceptibility pattern of ESBL-producing gram-negative bacilli. J Clin Diagn Res. 2011;5(2):236-39.
20.
Indian Council of Medical Research. Antimicrobial Resistance Research and Surveillance Network (AMRSN) annual report 2024 [Internet]. New Delhi: ICMR; 2025 [cited 2026 Jun 26]. Available from: https://www.icmr.gov.in.
21.
National Centre for Disease Control. Annual report 2024: National AMR Surveillance Network (NARS-Net) [Internet]. New Delhi: NCDC; 2025 [cited 2026 Jun 26]. Available from: https://ncdc.mohfw.gov.in.
22.
Pawar SK, Karande GS, Shinde RV, Pawar VS. Emergence of colistin-resistant gram-negative bacilli in a tertiary care rural hospital from Western India. Indian J Microbiol Res. 2016;3(3):308-13. [crossref]
23.
Singh A, Verma V, Singh R. Antibiotic sensitivity pattern of pathogens isolated from pus culture: A tertiary care hospital-based study. J Nepalgunj Med Coll. 2019;17:70-74. [crossref]
24.
Patil P, Chandi DH, Shelke D. Study of antibiotic sensitivity pattern of aerobic gram-positive organisms isolated from pus samples in a tertiary care hospital. Asian J Pharm Res Health Care. 2024;16(4):451-55.[crossref]

DOI and Others

DOI: 10.7860/JCDR/2026/89158.24694

Date of Submission: Mar 20, 2026
Date of Peer Review: Jun 03, 2026
Date of Acceptance: Aug 24, 2026
Date of Publishing: Dec 01, 2026

AUTHOR DECLARATION:

• Financial or Other Competing Interests: None
• Was Ethics Committee Approval obtained for this study? Yes
• Was informed consent obtained from the subjects involved in the study? NA
• For any images presented appropriate consent has been obtained from the subjects. NA

PLAGIARISM CHECKING METHODS:

• Plagiarism X-checker: Mar 30, 2026
• Manual Googling: Aug 18, 2026
• iThenticate Software: Aug 20, 2026 (1%)

ETYMOLOGY: Author Origin

EMENDATIONS: 6

JCDR is now Monthly and more widely Indexed .
  • Emerging Sources Citation Index (Web of Science, thomsonreuters)
  • Index Copernicus ICV 2017: 134.54
  • Academic Search Complete Database
  • Directory of Open Access Journals (DOAJ)
  • Embase
  • EBSCOhost
  • Google Scholar
  • HINARI Access to Research in Health Programme
  • Indian Science Abstracts (ISA)
  • Journal seek Database
  • Google
  • Popline (reproductive health literature)
  • www.omnimedicalsearch.com